4.0
Dec 24, 2025
Former employee, more than 5 years
Londres, Inglaterra
Recommend
CEO approval
Business Outlook
Pros
- Great products, solid growth - Talented ExCo members - Global presence, values-led
Cons
- Weak scientific leadership and weak drug pipeline - Too many 'experts' being allowed to do whatever they want, no results - AI/ML function poorly led and has wasted 100's of millions in investment